Superworth

Unicycive Therapeutics EPS UNCY

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
−$1.62
Latest quarter, Q2 FY26
−$0.06
Fiscal year 2025
−$2.04

Unicycive Therapeutics' earnings per share was −$1.62 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.06.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$2.04n/a
FY2024−$10.10n/a
FY2023−$16.10n/a
FY2022−$12.00n/a
FY2021−$7.90n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.06n/a−$1.62
Q1 FY26−$0.54n/a−$2.08
Q4 FY25−$0.69n/a−$2.04
Q3 FY25−$0.33n/a−$3.39
Q2 FY25−$0.52n/a−$3.52
Q1 FY25−$0.50n/a−$4.50
Q4 FY24−$2.04n/a−$10.10
Q3 FY24−$0.46n/a−$10.26
Q2 FY24−$1.50n/a−$11.10
Q1 FY24−$6.10n/a−$12.50
Q4 FY23−$2.20n/a−$16.10
Q3 FY23−$1.30n/a−$17.40

Against its peers

Companies in Drug Manufacturers - General nearest Unicycive Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
UNCYUnicycive Therapeutics−$1.62
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
NATRNatures Sunshine Products$1.01+36% a year
ATNMActinium Pharmaceuticals$0.36
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Unicycive Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.